Insight Molecular Diagnostics (IMDX)

• Market cap: $141M
• 1 day: 16.44%
• 5 days: -10.93%
• 1 month: -3.14%
• 3 months: -32.71%
• 6 months: -19.85%
• Year to date: -39.66%
• 1 year: 80%
• 5 years: -94.92%
• 10 years: -94.98%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Employees: 58